Key points are not available for this paper at this time.
efficacy vs. the research-grade vector. These findings establish AAV-vectorized cytokines as a durable, locally delivered immuno-gene therapy platform for high-grade gliomas.
Kuwahara et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: